CN103027788A - Absorbable medical dressing and preparation method thereof - Google Patents
Absorbable medical dressing and preparation method thereof Download PDFInfo
- Publication number
- CN103027788A CN103027788A CN2013100038061A CN201310003806A CN103027788A CN 103027788 A CN103027788 A CN 103027788A CN 2013100038061 A CN2013100038061 A CN 2013100038061A CN 201310003806 A CN201310003806 A CN 201310003806A CN 103027788 A CN103027788 A CN 103027788A
- Authority
- CN
- China
- Prior art keywords
- polymeric matrix
- temperature
- aqueous solution
- chitosan
- backing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000011159 matrix material Substances 0.000 claims abstract description 80
- 229920001661 Chitosan Polymers 0.000 claims abstract description 66
- 239000007864 aqueous solution Substances 0.000 claims abstract description 54
- 238000007710 freezing Methods 0.000 claims abstract description 17
- 230000008014 freezing Effects 0.000 claims abstract description 17
- 238000012805 post-processing Methods 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 10
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 6
- 239000004584 polyacrylic acid Substances 0.000 claims abstract description 6
- 239000004952 Polyamide Substances 0.000 claims abstract description 5
- 108010039918 Polylysine Proteins 0.000 claims abstract description 5
- 239000000783 alginic acid Substances 0.000 claims abstract description 5
- 229920000615 alginic acid Polymers 0.000 claims abstract description 5
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 5
- 229960001126 alginic acid Drugs 0.000 claims abstract description 5
- 150000004781 alginic acids Chemical class 0.000 claims abstract description 5
- 239000001913 cellulose Substances 0.000 claims abstract description 5
- 229920002678 cellulose Polymers 0.000 claims abstract description 5
- 229920002647 polyamide Polymers 0.000 claims abstract description 5
- 229920000656 polylysine Polymers 0.000 claims abstract description 5
- 102000008186 Collagen Human genes 0.000 claims abstract description 4
- 108010035532 Collagen Proteins 0.000 claims abstract description 4
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 4
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 4
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 3
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims abstract description 3
- 229920003232 aliphatic polyester Polymers 0.000 claims abstract description 3
- 230000003115 biocidal effect Effects 0.000 claims abstract description 3
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 3
- 229940014041 hyaluronate Drugs 0.000 claims abstract description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 3
- 229920002635 polyurethane Polymers 0.000 claims abstract description 3
- 239000004814 polyurethane Substances 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 31
- 239000000463 material Substances 0.000 claims description 26
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 24
- 238000005057 refrigeration Methods 0.000 claims description 15
- 229920000642 polymer Polymers 0.000 claims description 14
- 230000006835 compression Effects 0.000 claims description 10
- 238000007906 compression Methods 0.000 claims description 10
- 238000001816 cooling Methods 0.000 claims description 10
- 230000003111 delayed effect Effects 0.000 claims description 10
- 230000000630 rising effect Effects 0.000 claims description 10
- 230000002378 acidificating effect Effects 0.000 claims description 6
- 238000000280 densification Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 230000006196 deacetylation Effects 0.000 claims description 5
- 238000003381 deacetylation reaction Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000011067 equilibration Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 239000012943 hotmelt Substances 0.000 claims description 5
- 238000001746 injection moulding Methods 0.000 claims description 5
- 238000012423 maintenance Methods 0.000 claims description 5
- 230000014759 maintenance of location Effects 0.000 claims description 5
- 238000000465 moulding Methods 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 3
- 102000013275 Somatomedins Human genes 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 abstract 2
- 229920001436 collagen Polymers 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 3
- 230000005251 gamma ray Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000006448 coagulant property Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides an absorbable medical dressing. The absorbable medical dressing comprises an elastic backing and a polymeric matrix layer arranged on the backing, wherein the backing comprises at least one of polyurethane, hyaluronic acid, hyaluronate, absorbable aliphatic polyester and polyhydroxy butyric acid; the polymeric matrix layer comprises at least one of polyacrylic acid, alginic acid, chitosan, water-soluble polyamide, chitosan derivative, polylysine and cellulose derivative; a medicine layer is arranged on the polymeric matrix layer; and the medicine layer comprises at least one of collagen, fibrinogen, growth factor and antibiotic. A preparation method of the absorbable medical dressing comprises the following steps: (1) preparing a polymeric matrix aqueous solution; (2) injecting the prepared polymeric matrix aqueous solution into a mould; (3) freezing the polymeric matrix aqueous solution in the mould; (4) lyophilizing the frozen polymeric matrix aqueous solution; and (5) postprocessing polymeric matrix sponge to prepare the absorbable medical dressing.
Description
Technical field
The present invention relates to a kind of dressing and preparation method thereof, the spy is standby to be a kind of absorbability medical dressing and preparation method thereof.
Background technology
Wound is the serious problems of harm humans health, according to World Health Organization's trauma care guide, the whole world has 16000 people to cause death because of wound every day, and because wound to cause medical expense be up to 16% of all global medical expenses, wherein creating has 1/3 to be to cause death because of the relevant multiple organs failure of losing blood and lose blood among the wounded.If can stop blooding timely and effectively, to saving wounded's life, stablize traumatic condition, for successive treatment creates conditions very important.And dressing is as hemostatic material, refers to cover on wound, the covering of protective effect is arranged, and can assist Bleeding control, protects from infection and absorbs secretions, and bleeding-stopping dressing has great significance for timely hemostasis.Simultaneously, hemostasis to reduce in the art lose blood, keep the visual area clear, prevent the vital tissue damage, guarantee that operation safety and postoperative wound healing etc. are all significant.
Traditional bleeding-stopping dressing generally is by the adding bioactive molecule, such as thrombin and the former albumen of fiber, improve the anthemorrhagic performance of dressing, but the manufacturing cost of this class dressing is higher, and keeps the specific activity of such bioactive molecule difficult.Existing bleeding-stopping dressing is a kind of chitosan derivatives after polyacrylic acid modified, main performance is that water absorption is very excellent, but polyacrylic biological safety does not get the nod so far, the chitosan sthptic sponge that has on the market is the mandruka take chitosan and gelatin as main component, its humid stability is very poor, be easy to dissolve at the wound that a large amount of blood ooze out, can't bring into play coagulant property.
Summary of the invention
In order to solve the deficiencies in the prior art, the invention provides a kind of safe and reliable, absorbability medical dressing that humid stability is good and preparation method thereof.
The technical solution adopted for the present invention to solve the technical problems is:
A kind of absorbability medical dressing, comprise and have elastic backing and be arranged on polymer matrix layer on the backing, described backing is by polyurethane, hyaluronic acid, hyaluronate, at least a composition in absorbability aliphatic polyester or the poly butyric, polymer matrix layer is by polyacrylic acid, alginic acid, chitosan, water soluble polyamide, chitosan derivatives, at least a composition in polylysine or the cellulose derivative, be provided with medicine layer on the polymer matrix layer, described medicine layer is by collagen protein, Fibrinogen, at least a composition in somatomedin or the antibiotic.
Preferred as such scheme, described backing is the poly butyric material, the poly butyric material has good thermoplasticity, and can be degradable in vivo be carbon dioxide.
Described polymer matrix layer is comprised of chitosan, and chitosan has the biologic activity such as hemostatic bacteriostatic, and is Biodegradable material, can be degradable in vivo.
A kind of preparation method of aforesaid absorbability medical dressing may further comprise the steps:
(1) produces the polymeric matrix aqueous solution: choose polymeric matrix, polymeric matrix is polyacrylic acid, alginic acid, chitosan, water soluble polyamide, chitosan derivatives, at least a in polylysine or the cellulose derivative, the polymeric matrix that utilization is chosen prepares the polymeric matrix aqueous solution, add acidic materials and medicine in the polymeric matrix aqueous solution, the concentration of polymeric matrix is 0.1%～2.5% in the polymeric matrix aqueous solution that makes, the concentration of acidic materials is 0.5%～5%, acidic materials are glutamic acid, lactic acid, hydrochloric acid, in acetic acid or the glycolic any one, the mass ratio of medicine and polymeric matrix are 1:1000～1:10000;
(2) prepared polymeric matrix aqueous solution is injected mould: the length that is used for the mould of polymeric matrix aqueous solution injection molding is 60～70cm, width is 9～21cm, described mould has 3 chambers, and the height of chamber is 0.05～0.2cm, and width is 2～6cm;
(3) carry out freezing to the polymeric matrix aqueous solution in the mould: the mould that the polymeric matrix aqueous solution will be housed is inserted freeze dryer cryodesiccation chamber, described refrigerating process includes four steps, the first step is the hygral equilibrium process, temperature is 20～25 ℃ in the hygral equilibrium process, and equilibration time is 2～5h; Second step is temperature-fall period, is cooled to 2～10 ℃ with the rate of temperature fall of 0.3～1.0 ℃/min, and keeps temperature 20～60min of 2～10 ℃; The 3rd step was the deferring procedure of lowering the temperature, and the rate of temperature fall continuation cooling with 0.3～1.0 ℃/min when the cooling temperature reaches-5 ℃, needs the of short duration stage of rising again of maintenance, and the temperature of rising again is-3～0 ℃, and the retention time is 3～5min; The 4th step is for continuing temperature-fall period, continues to be cooled to-40 ℃ with the rate of temperature fall of 0.3～1.0 ℃/min, and at-40 ℃ of freezing 30～60min.After freezing the finishing, obtain refrigeration material;
(4) refrigeration material is carried out lyophilizing: be-80 in negative pressure～-environment of 20KPa in to the refrigeration material lyophilizing, lyophilizing includes four steps, the first step is the stage of being rapidly heated, temperature is rapidly heated to 0 ℃ by cryogenic temperature, the heating-up time is 20～50min; Second step is delayed phase, and temperature remains on 0 ℃, and be 400～600min time delay; The 3rd step, temperature was rapidly heated to 35～40 ℃ by 0 ℃ in order continuing the stage of being rapidly heated, and the heating-up time is 20～50min; The 4th step, temperature remained on 35～40 ℃ of intensification temperature in order to continue delayed phase, and be 1000～2000min time delay; After lyophilizing is finished, obtain the polymeric matrix sponge;
(5) the polymeric matrix sponge is carried out post processing, make the absorbability medical dressing: described post processing comprises three steps, the first step is the densification stage, utilize hot melt that polymeric matrix sponge and backing are fitted, take again the hot plate compression method, make polymeric matrix sponge and backing bonding, the temperature that the hot plate compression method is selected is 75～85 ℃, moulding pressure is 0.5～0.6MPa, and the thickness of resulting polymers substrate sponge is 0.6～10mm, and density is 0.1～0.5g/m
3Second step is pretreatment stage, and with polymeric matrix sponge and backing baking, bake out temperature is 75～80 ℃, and drying time is 0.25～0.5h.The 3rd goes on foot the processing stage of being softening, adopts softening machine that polymeric matrix sponge and backing are softened, and makes the absorbability medical dressing, and the Gurley hardness number of resulting polymers substrate sponge is 2000～10000.
Preferred as such scheme, described polymeric matrix is that molecular weight is the chitosan of 150～300,000 Dao Er, the deacetylation of chitosan is 80%～95%.
In the step (1), need in the preparation process of polymeric matrix aqueous solution the polymeric matrix aqueous solution is carried out vacuum deaerator, the pressure of vacuum deaerator is-8 * 10
5～-3 * 10
5Pa, the deaeration time is 5～30min.
The present invention than the beneficial effect that prior art has is: absorbability medical dressing provided by the invention and preparation method thereof, adopt the good polymeric matrix of absorbability as polymer matrix layer, and be provided with carrier layer in polymer matrix layer, carrier layer is the ingredients with healing property, safety and the curative effect of dressing have been improved, and by techniques such as freezing, lyophilizing, densification, pretreatment and softening processing, change the hardness of dressing, improved the humid stability of dressing.
The specific embodiment
The invention will be further described below in conjunction with embodiment.
In present embodiment 1, at first produce the polymeric matrix aqueous solution: choosing molecular weight is the chitosan 455g of 300,000 Dao Er, the deacetylation of chitosan is 95%, the chitosan that utilization is chosen prepares chitosan aqueous solution, add acetic acid and 0.4g collagen protein in the chitosan aqueous solution, the concentration of chitosan is 2.3% in the chitosan aqueous solution that makes, and the concentration of acetic acid is 4%, need in the chitosan aqueous solution preparation process chitosan aqueous solution is carried out vacuum deaerator, deaeration pressure is-3 * 10
5Pa, the deaeration time is 5min;
Secondly prepared polymeric matrix aqueous solution is injected mould: the length that is used for the mould of polymeric matrix aqueous solution injection molding is 60～70cm, width is 9～21cm, described mould has 3 chambers, and the height of chamber is 0.05～0.2cm, and width is 2～6cm;
Then the chitosan aqueous solution in the mould is carried out freezing: the mould that chitosan aqueous solution will be housed is inserted freeze dryer cryodesiccation chamber, described refrigerating process includes four steps, the first step is the hygral equilibrium process, and temperature is preferably 25 ℃ in the hygral equilibrium process, and equilibration time is preferably 5h; Second step is temperature-fall period, is cooled to 2 ℃ with the rate of temperature fall of 0.5 ℃/min, and keeps 2 ℃ temperature 60min; The 3rd step was the deferring procedure of lowering the temperature, and the rate of temperature fall continuation cooling with 0.5 ℃/min when the cooling temperature reaches-5 ℃, needs the of short duration stage of rising again of maintenance, and the temperature of rising again is-3 ℃, and the retention time is 5min; The 4th step is for continuing temperature-fall period, continues to be cooled to-40 ℃ with the rate of temperature fall of 0.5 ℃/min, and at-40 ℃ of freezing 30min.After freezing the finishing, obtain refrigeration material;
Then refrigeration material is carried out lyophilizing: negative pressure for the environment of-80KPa in to the refrigeration material lyophilizing, lyophilizing includes four steps, the first step is the stage of being rapidly heated, temperature is rapidly heated to 0 ℃ by cryogenic temperature, the heating-up time is 50min; Second step is delayed phase, and temperature remains on 0 ℃, and be 600min time delay; The 3rd step, temperature was rapidly heated to 40 ℃ by 0 ℃ in order continuing the stage of being rapidly heated, and the heating-up time is 40min; The 4th step, temperature remained on 40 ℃ of intensification temperature in order to continue delayed phase, and be 2000min time delay; After lyophilizing is finished, obtain chitosan sponge;
Next step carries out post processing with chitosan sponge: described post processing comprises three steps, the first step is the densification stage, utilize hot melt that chitosan sponge and backing are fitted, take again the hot plate compression method, make polymeric matrix sponge and backing bonding, the temperature that the hot plate compression method is selected is 80 ℃, and moulding pressure is 0.5MPa, the thickness of gained chitosan sponge is 10mm, and density is 0.1g/m
3Second step is pretreatment stage, takes baking, and bake out temperature is 80 ℃, and drying time is 0.5h.The 3rd goes on foot the processing stage of being softening, adopts softening machine that polymeric matrix sponge and backing are softened, and makes the absorbability medical dressing, and the Gurley hardness number of gained chitosan sponge is 4000.
Then the dressing that assembles is cut, encapsulation is also sterilized with the 19kGy gamma ray.
In present embodiment 2, at first produce the polymeric matrix aqueous solution: choosing molecular weight is the chitosan 455g of 150,000 Dao Er, the deacetylation of chitosan is 85%, the chitosan that utilization is chosen prepares chitosan aqueous solution, add acetic acid and 0.4 g somatomedin in the chitosan aqueous solution, the concentration of chitosan is 0.1% in the chitosan aqueous solution that makes, and the concentration of acetic acid is 0.8%, need in the chitosan aqueous solution preparation process chitosan aqueous solution is carried out vacuum deaerator, deaeration pressure is-8 * 10
5Pa, the deaeration time is 30min;
Secondly prepared polymeric matrix aqueous solution is injected mould: the length that is used for the mould of polymeric matrix aqueous solution injection molding is 60～70cm, width is 9～21cm, described mould has 3 chambers, and the height of chamber is 0.05～0.2cm, and width is 2～6cm;
Then the chitosan aqueous solution in the mould is carried out freezing: the mould that chitosan aqueous solution will be housed is inserted freeze dryer cryodesiccation chamber, described refrigerating process includes four steps, the first step is the hygral equilibrium process, and temperature is preferably 20 ℃ in the hygral equilibrium process, and equilibration time is preferably 2h; Second step is temperature-fall period, is cooled to 10 ℃ with the rate of temperature fall of 0.3 ℃/min, and keeps 10 ℃ temperature 20min; The 3rd step was the deferring procedure of lowering the temperature, and the rate of temperature fall continuation cooling with 0.3 ℃/min when the cooling temperature reaches-5 ℃, needs the of short duration stage of rising again of maintenance, and the temperature of rising again is 0 ℃, and the retention time is 3min; The 4th step is for continuing temperature-fall period, continues to be cooled to-40 ℃ with the rate of temperature fall of 0.3 ℃/min, and at-40 ℃ of freezing 50min.After freezing the finishing, obtain refrigeration material;
Then refrigeration material is carried out lyophilizing: negative pressure for the environment of-20KPa in to the refrigeration material lyophilizing, lyophilizing includes four steps, the first step is the stage of being rapidly heated, temperature is rapidly heated to 0 ℃ by cryogenic temperature, the heating-up time is 20min; Second step is delayed phase, and temperature remains on 0 ℃, and be 400min time delay; The 3rd step, temperature was rapidly heated to 40 ℃ by 0 ℃ in order continuing the stage of being rapidly heated, and the heating-up time is 20min; The 4th step, temperature remained on 40 ℃ of intensification temperature in order to continue delayed phase, and be 1300min time delay; After lyophilizing is finished, obtain chitosan sponge;
Next step carries out post processing with chitosan sponge: described post processing comprises three steps, described post processing comprises three steps, the first step is the densification stage, utilize hot melt that polymeric matrix sponge and backing are fitted, take again the hot plate compression method, make polymeric matrix sponge and backing bonding, the temperature that the hot plate compression method is selected is 75 ℃, moulding pressure is 0.6MPa, and the thickness of gained chitosan sponge is 0.6mm, and density is 0.3g/m
3Second step is pretreatment stage, takes baking, and bake out temperature is 75 ℃, and drying time is 0.25h.The 3rd goes on foot the processing stage of being softening, adopts softening machine that polymeric matrix sponge and backing are softened, and makes the absorbability medical dressing, and the Gurley hardness number of gained chitosan sponge is 2000.
Then the dressing that assembles is cut, encapsulation is also sterilized with the 15kGy gamma ray.
In present embodiment 3, at first produce the polymeric matrix aqueous solution: choosing molecular weight is the chitosan 455g of 200,000 Dao Er, the deacetylation of chitosan is 90%, the chitosan that utilization is chosen prepares chitosan aqueous solution, add acetic acid and 0.04g Fibrinogen in the chitosan aqueous solution, the concentration of chitosan is 1% in the chitosan aqueous solution that makes, and the concentration of acetic acid is 2%, need in the chitosan aqueous solution preparation process chitosan aqueous solution is carried out vacuum deaerator, deaeration pressure is-5 * 10
5Pa, the deaeration time is 20min;
Secondly prepared polymeric matrix aqueous solution is injected mould: the length that is used for the mould of polymeric matrix aqueous solution injection molding is 60～70cm, width is 9～21cm, described mould has 3 chambers, and the height of chamber is 0.05～0.2cm, and width is 2～6cm;
Then the chitosan aqueous solution in the mould is carried out freezing: the mould that chitosan aqueous solution will be housed is inserted freeze dryer cryodesiccation chamber, described refrigerating process includes four steps, the first step is the hygral equilibrium process, and temperature is preferably 22 ℃ in the hygral equilibrium process, and equilibration time is preferably 3h; Second step is temperature-fall period, is cooled to 5 ℃ with the rate of temperature fall of 0.4 ℃/min, and keeps 5 ℃ temperature 40min; The 3rd step was the deferring procedure of lowering the temperature, and the rate of temperature fall continuation cooling with 0.4 ℃/min when the cooling temperature reaches-5 ℃, needs the of short duration stage of rising again of maintenance, and the temperature of rising again is-2 ℃, and the retention time is 4min; The 4th step is for continuing temperature-fall period, continues to be cooled to-40 ℃ with the rate of temperature fall of 0.4 ℃/min, and at-40 ℃ of freezing 60min.After freezing the finishing, obtain refrigeration material;
Then refrigeration material is carried out lyophilizing: negative pressure for the environment of-50KPa in to the refrigeration material lyophilizing, lyophilizing includes four steps, the first step is the stage of being rapidly heated, temperature is rapidly heated to 0 ℃ by cryogenic temperature, the heating-up time is 30min; Second step is delayed phase, and temperature remains on 0 ℃, and be 500min time delay; The 3rd step, temperature was rapidly heated to 40 ℃ by 0 ℃ in order continuing the stage of being rapidly heated, and the heating-up time is 30min; The 4th step, temperature remained on 40 ℃ of intensification temperature in order to continue delayed phase, and be 1600min time delay; After lyophilizing is finished, obtain chitosan sponge;
Next step carries out post processing with chitosan sponge: described post processing comprises three steps, described post processing comprises three steps, the first step is the densification stage, utilize hot melt that polymeric matrix sponge and backing are fitted, take again the hot plate compression method, make polymeric matrix sponge and backing bonding, the temperature that the hot plate compression method is selected is 85 ℃, moulding pressure is 0.6MPa, and the thickness of gained chitosan sponge is 0.8mm, and density is 0.2g/m
3Second step is pretreatment stage, takes baking, and bake out temperature is 78 ℃, and drying time is 0.4h.The 3rd goes on foot the processing stage of being softening, adopts softening machine that polymeric matrix sponge and backing are softened, and makes the absorbability medical dressing, and the Gurley hardness number of gained chitosan sponge is 3000.
Then the dressing that assembles is cut, encapsulation is also sterilized with the 17kGy gamma ray.
Claims (6)
1. absorbability medical dressing, it is characterized in that: comprise having elastic backing and be arranged on polymer matrix layer on the backing, described backing is by polyurethane, hyaluronic acid, hyaluronate, at least a composition in absorbability aliphatic polyester or the poly butyric, polymer matrix layer is by polyacrylic acid, alginic acid, chitosan, water soluble polyamide, chitosan derivatives, at least a composition in polylysine or the cellulose derivative, be provided with medicine layer on the polymer matrix layer, described medicine layer is by collagen protein, Fibrinogen, at least a composition in somatomedin or the antibiotic.
2. medical dressing according to claim 1, it is characterized in that: described backing is the poly butyric material.
3. medical dressing according to claim 1, it is characterized in that: described polymer matrix layer is comprised of chitosan.
4. the preparation method of an absorbability medical dressing as claimed in claim 1 is characterized in that may further comprise the steps:
(1) produces the polymeric matrix aqueous solution: choose polymeric matrix, polymeric matrix is polyacrylic acid, alginic acid, chitosan, water soluble polyamide, chitosan derivatives, at least a in polylysine or the cellulose derivative, the polymeric matrix that utilization is chosen prepares the polymeric matrix aqueous solution, add acidic materials and medicine in the polymeric matrix aqueous solution, the concentration of polymeric matrix is 0.1%～2.5% in the polymeric matrix aqueous solution that makes, the concentration of acidic materials is 0.5%～5%, acidic materials are glutamic acid, lactic acid, hydrochloric acid, in acetic acid or the glycolic any one, the mass ratio of medicine and polymeric matrix are 1:1000～1:10000;
(2) prepared polymeric matrix aqueous solution is injected mould: the length that is used for the mould of polymeric matrix aqueous solution injection molding is 60～70cm, width is 9～21cm, described mould has 3 chambers, and the height of chamber is 0.05～0.2cm, and width is 2～6cm;
(3) carry out freezing to the polymeric matrix aqueous solution in the mould: the mould that the polymeric matrix aqueous solution will be housed is inserted freeze dryer cryodesiccation chamber, described refrigerating process includes four steps, the first step is the hygral equilibrium process, temperature is 20～25 ℃ in the hygral equilibrium process, and equilibration time is 2～5h; Second step is temperature-fall period, is cooled to 2～10 ℃ with the rate of temperature fall of 0.3～1.0 ℃/min, and keeps temperature 20～60min of 2～10 ℃; The 3rd step was the deferring procedure of lowering the temperature, and the rate of temperature fall continuation cooling with 0.3～1.0 ℃/min when the cooling temperature reaches-5 ℃, needs the of short duration stage of rising again of maintenance, and the temperature of rising again is-3～0 ℃, and the retention time is 3～5min; The 4th step is for continuing temperature-fall period, continues to be cooled to-40 ℃ with the rate of temperature fall of 0.3～1.0 ℃/min, and at-40 ℃ of freezing 30～60min.After freezing the finishing, obtain refrigeration material;
(4) refrigeration material is carried out lyophilizing: be-80 in negative pressure～-environment of 20KPa in to the refrigeration material lyophilizing, lyophilizing includes four steps, the first step is the stage of being rapidly heated, temperature is rapidly heated to 0 ℃ by cryogenic temperature, the heating-up time is 20～50min; Second step is delayed phase, and temperature remains on 0 ℃, and be 400～600min time delay; The 3rd step, temperature was rapidly heated to 35～40 ℃ by 0 ℃ in order continuing the stage of being rapidly heated, and the heating-up time is 20～50min; The 4th step, temperature remained on 35～40 ℃ of intensification temperature in order to continue delayed phase, and be 1000～2000min time delay; After lyophilizing is finished, obtain the polymeric matrix sponge;
(5) the polymeric matrix sponge is carried out post processing, make the absorbability medical dressing: described post processing comprises three steps, the first step is the densification stage, utilize hot melt that polymeric matrix sponge and backing are fitted, take again the hot plate compression method, make polymeric matrix sponge and backing bonding, the temperature that the hot plate compression method is selected is 75～85 ℃, moulding pressure is 0.5～0.6MPa, and the thickness of resulting polymers substrate sponge is 0.6～10mm, and density is 0.1～0.5g/m
3Second step is pretreatment stage, and with polymeric matrix sponge and backing baking, bake out temperature is 75～80 ℃, and drying time is 0.25～0.5h.The 3rd goes on foot the processing stage of being softening, adopts softening machine that polymeric matrix sponge and backing are softened, and makes the absorbability medical dressing, and the Gurley hardness number of resulting polymers substrate sponge is 2000～10000.
5. preparation method according to claim 5, it is characterized in that: described polymeric matrix is that molecular weight is the chitosan of 150～300,000 Dao Er, and the deacetylation of chitosan is 80%～95%.
6. preparation method according to claim 5, it is characterized in that: in the step (1), need in the preparation process of polymeric matrix aqueous solution the polymeric matrix aqueous solution is carried out vacuum deaerator, the pressure of vacuum deaerator is-8 * 10
5～3 * 10
5Pa, the deaeration time is 5～30min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310003806.1A CN103027788B (en) | 2013-01-05 | 2013-01-05 | Preparation method of absorbable medical dressing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310003806.1A CN103027788B (en) | 2013-01-05 | 2013-01-05 | Preparation method of absorbable medical dressing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103027788A true CN103027788A (en) | 2013-04-10 |
| CN103027788B CN103027788B (en) | 2014-11-19 |
Family
ID=48015534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310003806.1A Active CN103027788B (en) | 2013-01-05 | 2013-01-05 | Preparation method of absorbable medical dressing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103027788B (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103623454A (en) * | 2013-11-28 | 2014-03-12 | 北京健康广济贸易有限公司 | High-permeability film dressing |
| CN104497348A (en) * | 2014-12-31 | 2015-04-08 | 武汉奥绿新生物科技有限公司 | Softening technology and equipment for polysaccharides lyophilized sponge dressing |
| CN106139230A (en) * | 2015-04-21 | 2016-11-23 | 胡庆柳 | One has bioactive medical dressing and preparation method thereof |
| CN109289078A (en) * | 2018-11-02 | 2019-02-01 | 广东药科大学 | A kind of long-acting bacteriostatic adhesive bandage |
| CN111671975A (en) * | 2020-07-01 | 2020-09-18 | 江南大学 | Composite artificial skin material for repairing skin injury |
| CN115626982A (en) * | 2022-11-02 | 2023-01-20 | 中山大学 | Nitroxide-free-radical-modified lysine-based polyesteramide polymer and preparation method and application thereof |
| CN116726241A (en) * | 2023-08-11 | 2023-09-12 | 江苏亨瑞生物医药科技有限公司 | Collagen hemostatic and antibacterial dressing and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1095916A (en) * | 1993-03-22 | 1994-12-07 | 布里斯托尔-迈尔斯斯奎布公司 | Polymer is made the wound dressing of bottom |
| CN2920163Y (en) * | 2006-04-20 | 2007-07-11 | 中山大学附属第二医院 | Nanometer hemostatic plaster |
| CN100379463C (en) * | 2002-12-19 | 2008-04-09 | 3M创新有限公司 | Absorbent medical articles |
| CN101801322A (en) * | 2007-09-28 | 2010-08-11 | 日绊株式会社 | Patch material |
-
2013
- 2013-01-05 CN CN201310003806.1A patent/CN103027788B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1095916A (en) * | 1993-03-22 | 1994-12-07 | 布里斯托尔-迈尔斯斯奎布公司 | Polymer is made the wound dressing of bottom |
| CN100379463C (en) * | 2002-12-19 | 2008-04-09 | 3M创新有限公司 | Absorbent medical articles |
| CN2920163Y (en) * | 2006-04-20 | 2007-07-11 | 中山大学附属第二医院 | Nanometer hemostatic plaster |
| CN101801322A (en) * | 2007-09-28 | 2010-08-11 | 日绊株式会社 | Patch material |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103623454A (en) * | 2013-11-28 | 2014-03-12 | 北京健康广济贸易有限公司 | High-permeability film dressing |
| CN103623454B (en) * | 2013-11-28 | 2015-04-22 | 北京健康广济贸易有限公司 | High-permeability film dressing |
| CN104497348A (en) * | 2014-12-31 | 2015-04-08 | 武汉奥绿新生物科技有限公司 | Softening technology and equipment for polysaccharides lyophilized sponge dressing |
| CN104497348B (en) * | 2014-12-31 | 2018-10-26 | 武汉奥绿新生物科技股份有限公司 | A kind of submissiveization Processes and apparatus of poly- polysaccharide freeze-drying sponge dressing |
| CN106139230A (en) * | 2015-04-21 | 2016-11-23 | 胡庆柳 | One has bioactive medical dressing and preparation method thereof |
| CN109289078A (en) * | 2018-11-02 | 2019-02-01 | 广东药科大学 | A kind of long-acting bacteriostatic adhesive bandage |
| CN111671975A (en) * | 2020-07-01 | 2020-09-18 | 江南大学 | Composite artificial skin material for repairing skin injury |
| CN115626982A (en) * | 2022-11-02 | 2023-01-20 | 中山大学 | Nitroxide-free-radical-modified lysine-based polyesteramide polymer and preparation method and application thereof |
| CN115626982B (en) * | 2022-11-02 | 2024-03-08 | 中山大学 | Nitrogen-oxygen free radical modified lysine-based polyester amide polymer and preparation method and application thereof |
| CN116726241A (en) * | 2023-08-11 | 2023-09-12 | 江苏亨瑞生物医药科技有限公司 | Collagen hemostatic and antibacterial dressing and preparation method thereof |
| CN116726241B (en) * | 2023-08-11 | 2023-10-20 | 江苏亨瑞生物医药科技有限公司 | Collagen hemostatic and antibacterial dressing and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103027788B (en) | 2014-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103027788B (en) | Preparation method of absorbable medical dressing | |
| CN103028135B (en) | Method for preparing hemostatic sponge for dressing | |
| CN103599558B (en) | A kind of quick hemostatic dressing and preparation method thereof | |
| CN102961777B (en) | Method for preparing porous compound type high permeability absorption hemostasis coating with modified nano-crystalline cellulose | |
| CN103536954B (en) | A kind of crosslinked alginic acid-bacteria cellulose sponges and preparation method thereof | |
| CN105288706A (en) | Rapid bleeding-stopping dressing for department of gynaecology and obstetrics and preparation method of rapid bleeding-stopping dressing | |
| CN103012836B (en) | Preparation method of polysaccharide sponge for material dressing | |
| CN112826975B (en) | Medical chitosan rapid hemostatic dressing and preparation method thereof | |
| CN101954126A (en) | Method for preparing bionic modified collagen tissue repair material | |
| CN103483625A (en) | Absorbable and degradable multipurpose biocompatible material | |
| CN103611180B (en) | Preparation method of self-adhesion hemostasis anti-adhesion corpus fibrosum | |
| CN103751833B (en) | Medical antibacterial wound dressing and preparation method thereof | |
| CN102228695A (en) | Method for preparing basic fibroblast growth factor sustained-release carrier | |
| KR20160009724A (en) | Polymer Foam Composition, Method Of Producing Polymer Foam Using The Same, And Polymer Foam for Packing Therefrom | |
| CN102671231B (en) | Method for preparing marine-derived compound collagen dressing | |
| CN108478846A (en) | A kind of medical hemostatic antiseptic dressing and preparation method thereof | |
| CN103611195A (en) | Self-adhesion hemostasis anti-adhesion corpus fibrosum | |
| EP2595667B1 (en) | Collagenous material | |
| CN102600495A (en) | Absorbable hemostatic composition and preparation method thereof | |
| CN101703799A (en) | Preparation of anti-coagulation dermis scaffold | |
| CN104497345A (en) | Preparation method of hyaluronic acid-chitosan degradable dressing | |
| CN106913908B (en) | Cell growth support with structure memory characteristic | |
| Pal Kaur et al. | Material couture for wound healing and regeneration: an overview | |
| CN113750286B (en) | Skin wound covering film and preparation method thereof | |
| CN102178691B (en) | Starch stypticum and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: ZHANG RUI ZHU SIJIE Effective date: 20141014 Owner name: WUHAN AOLVXIN BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: WU BIN Effective date: 20141014 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 430060 WUHAN, HUBEI PROVINCE TO: 430074 WUHAN, HUBEI PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20141014 Address after: 430074 A-406, Wuhan international business center, Optics Valley Road, Hubei, China Applicant after: WUHAN GREENOVO BIOTECHNOLOGY Co.,Ltd. Address before: 430060 No. 185, East Lake Road, Wuchang District, Hubei, Wuhan Applicant before: Wu Bin Applicant before: Zhang Rui Applicant before: Zhu Sijie |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 430074 A-406, Wuhan international business center, Optics Valley Road, Hubei, China Patentee after: WUHAN GREENOVO BIOTECHNOLOGY CO.,LTD. Address before: 430074 A-406, Wuhan international business center, Optics Valley Road, Hubei, China Patentee before: WUHAN GREENOVO BIOTECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240918 Address after: Building A2-1, Unit 2, 2nd Floor, Optics Valley Biomedical Park, 858 Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan City, Hubei Province 430040 Patentee after: Wuhan Aomukang Medical Technology Co.,Ltd. Country or region after: China Address before: A-406 Dingye Building, Guanggu Avenue International Enterprise Center, Wuhan City, Hubei Province 430074 Patentee before: WUHAN GREENOVO BIOTECHNOLOGY CO.,LTD. Country or region before: China |